Isoray Completes Merger with Viewpoint Molecular Targeting
February 6, 2023
Isoray, Inc. completed an all-stock merger with Viewpoint Molecular Targeting, effective February 3, 2023, combining Isoray's brachytherapy expertise with Viewpoint's radiopharmaceutical and diagnostic pipeline. Under the deal each Viewpoint share converted into 3.1642 shares of Isoray (totaling 136,545,075 shares, ~49% of Isoray's outstanding shares); Viewpoint CEO Thijs Spoor was named CEO of the combined company and outgoing Isoray CEO Lori Woods became Chair.
- Buyers
- Isoray, Inc.
- Targets
- Viewpoint Molecular Targeting, Inc.
- Industry
- Biotechnology
- Location
- Iowa, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.